Anti-Parkinson's disease drugs and pharmacogenetic considerations. [electronic resource]
Producer: 20140204Description: 859-74 p. digitalISSN:- 1744-7607
- Aryl Hydrocarbon Hydroxylases -- genetics
- Benzothiazoles -- therapeutic use
- Benztropine -- therapeutic use
- Bromocriptine -- therapeutic use
- Cabergoline
- Catechols -- therapeutic use
- Cytochrome P-450 CYP1A2 -- metabolism
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP2B6
- Cytochrome P-450 CYP2C19
- Cytochrome P-450 CYP3A -- genetics
- Ergolines -- therapeutic use
- Genetic Markers
- Humans
- Indans -- therapeutic use
- Indoles -- therapeutic use
- Levodopa -- therapeutic use
- Lisuride -- therapeutic use
- Nitriles -- therapeutic use
- Parkinson Disease -- drug therapy
- Pergolide -- therapeutic use
- Pharmacogenetics
- Pramipexole
- Receptors, Dopamine D2 -- genetics
- Receptors, Dopamine D3 -- genetics
- Reproducibility of Results
- Selegiline -- therapeutic use
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.